NCT05216965

A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors

Phase I/II Clinical Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of 9MW2821 in Subjects With Advanced Malignant Solid Tumors

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 208 (estimated)
• Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is a Phase 1/2, first-in-human, open-label, dose-escalation and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, preliminary antitumor activity and immunogenicity of 9MW2821 administered by intravenous (IV) infusion.

Conditions

• Solid Tumors

Interventions

Type	Name	Description
DRUG	9MW2821	All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).

Timeline

• Start date: 2022-06-11
• Primary completion: 2025-12-01
• Completion: 2025-12-01
• First posted: 2022-02-01
• Last updated: 2022-06-15

Locations

1 site across 1 country: China